<DOC>
	<DOCNO>NCT02299804</DOCNO>
	<brief_summary>A Multicenter , Double-Blind , Placebo Controlled , Phase â…¡a clinical trial enroll 120 patient Vertigo Caused By Posterior Circulation Infarction 7 day , evaluate efficacy different dose Levophencynonate Hydrochloric , provide effective dosage phase IIb clinical study , study safety Levophencynonate Hydrochloric .</brief_summary>
	<brief_title>A Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo</brief_title>
	<detailed_description>This study conduct 15 site enrol 120 patient vertigo 7 day treatment 7 day follow-up . The study include three arm : high dose , low dose placebo control.To observe efficacy change vertigo severity duration , safety vital sign , adverse event , etc .</detailed_description>
	<mesh_term>Vertigo</mesh_term>
	<mesh_term>Dizziness</mesh_term>
	<criteria>1 . At age 18 year old male female ; 2 . Patients vertigo cause Posterior Circulation Infarction . 3 . Patients diagnose Posterior Circulation Infarction base criterion Posterior Circulation Ischemia America ; 4 . Meet diagnose criterion vertigo : Visual Motion ( External Vertigo ) , Rotation , Swing , Lift Tilt Sensation ( Internal Vertigo ) ; 5 . Ability sign statement informed consent ; 1 . Female patient Pregnant , Lactating Birth plan recently ; 2 . Nonposterior circulation infarction patient ; 3 . Vertigo cause disease ; 4 . Longterm alcohol abuse , drug abuse ; 5 . Been critical condition , difficult make precise evaluation efficacy safety new drug ; 6 . History allergy Levophencynonate Hydrochloric composition ; 7 . Participation another clinical trial three month ; 8 . Investigator think exclude due reason ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>